Bispecifics in Discovery and Development Congress

Memo

We will welcome over 400 senior discovery attendees representing global pharmaceutical organisations, leading biotech companies and internationally renowned academic institutions. Over 18 presentations and case studies focusing on the latest trends and technologies in Bispecifics discovery as well as the considerations for immunogenicity, safety, CMC, biomarkers in bringing Bispecific in clinic. The congress also explores the role of Bispecific antibodies in paving the next wave of biotherapeutics. Including 2 interactive streams: - Bispecific Discovery, Therapeutic Development and Developability Considerations - Preclinical Development, Translation and Clinical Development in Bispecific Antibodies Co-located with the 20th Annual Drug Discovery Summit, 7th Annual Discovery Chemistry and Drug Design Congress and Neuroscience in Discovery and Development Congress. 14 pre-scheduled one to one meetings, exhibition spaces and informal networking opportunities URLs:Tickets: https://go.evvnt.com/380925-2?pid=5569 Brochure: https://go.evvnt.com/380925-3?pid=5569 PriceRegistration Available from: EUR 360.0 Speakers: John Delaney, Executive Director, Research, Amgen, Antonio de Fougerolles, CEO, Evox Therapeutics, Christophe Blanchetot, Director Discovery, Argenx BVBA, Mark Throsby, CSO, Merus,  Mihriban Tuna, Vice President, Drug Discovery, F-Star, Bryan Glaser, Vice President of Biologics Development, Invenra,  Nathan Trinklein, VP, Discovery, Teneobio, Teemu Junttila, Senior Scientist, Translational Oncology, Genentech,   Nina E. Weisser, Principal Scientist Zymeworks Tuesday June 11, 2019 at 7:30 am (ends Wednesday June 12, 2019 at 6:00 pm) Venue details: Maritim proArte Hotel Berlin, 151 Friedrichstraße, Berlin 10117, Germany